PA
ACAD icon

Perceptive Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Perceptive Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-200,000
Closed -$2.8M – 173
2016
Q1 		$2.8M Buy
+200,000
New +$4.36M 0.25% 77

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Perceptive Advisors's ACAD Position: Q1 2024 in Review

Perceptive Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 101,000 shares — an estimated $3.16M sold.

Perceptive Advisors first reported a position in ACAD in Q2 2013 and held it in 20 quarters. The position peaked at $37M in Q4 2021. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Perceptive Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Perceptive Advisors sold 101,000 Acadia Pharmaceuticals shares in Q1 2024, an estimated $3.16M.
  • Perceptive Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Perceptive Advisors's Acadia Pharmaceuticals position peaked at $37M in Q4 2021.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.